U.S. Healthcare Services Stock News

Dell Technologies (DELL) has put AI at the center of its story, raising its fiscal 2026 AI server sales forecast to US$25b, acquiring Dataloop, and rolling out the One Dell Way modernization program. See our latest analysis for Dell Technologies. Despite Dell’s busy year of AI focused product launches, acquisitions and the One Dell Way overhaul, momentum has cooled recently, with a 90 day share price return showing a 22.15% decline, even as the 5 year total shareholder return of 244.68%...

Recently, Tidewater outlined 2026 revenue guidance of US$1.32 billion to US$1.37 billion and confirmed it still has US$500 million available under its share repurchase authorization, against a backdrop of firmer crude oil prices and a softer U.S. jobs report that supported offshore energy sentiment. This combination of firmer long-term revenue expectations and potential capital returns has sharpened attention on how Tidewater might balance growth investment with shareholder-focused uses of...

The latest move from Cadence Design Systems (CDNS) centers on two product announcements that tie the business more tightly to AI hardware, including a new LPDDR5X memory IP solution with Microsoft as the first customer. See our latest analysis for Cadence Design Systems. Those AI focused launches come after a steady year in the market, with a 1 year total shareholder return of 9.81% and a 3 year total shareholder return of 86.77%, while the current share price sits at US$323.06. If Cadence’s...

Why Morgan Stanley Is Back On Investors’ Radar Morgan Stanley (MS) is drawing fresh attention as investors reassess its recent share performance in the context of its global wealth management, institutional securities, and investment management franchises. See our latest analysis for Morgan Stanley. Recent trading has been a bit choppy, with a 1-day share price return of a 2.04% decline and a 7-day share price return of a 2.66% decline, while a 90-day share price return of 12.36% alongside a...

Why the 24/7 Care upgrade matters for Teladoc Health stock Teladoc Health (TDOC) has rolled out a nationwide upgrade to its 24/7 Care service, expanding virtual urgent care to more conditions, adding real-time specialist consults, and integrating preventive care and prescription benefit checks. See our latest analysis for Teladoc Health. Even with the 24/7 Care upgrade and a recent appearance at the J.P. Morgan Healthcare Conference, Teladoc Health’s share price has been weak, with a 7 day...

Federal housing policy is back in focus after President Donald Trump directed the purchase of US$200b in mortgage bonds, a move aimed at lowering borrowing costs and directly affecting demand for builders such as D.R. Horton (DHI). See our latest analysis for D.R. Horton. The policy driven rebound that lifted D.R. Horton after the US$200b mortgage bond announcement comes on top of a 7 day share price return of 11.31% and a year to date share price return of 10.38%, while the 5 year total...

In early January 2026, Omnicom Group Inc. unveiled the next generation of its Omni marketing intelligence platform, integrating advanced AI, Acxiom RealID-powered identity data spanning 2.60 billion verified IDs, Flywheel Commerce Cloud signals, and autonomous agent systems into a unified operating system for marketers. This upgraded Omni platform uniquely combines one of the industry's most extensive consumer identity infrastructures with AI-native creative and media tools, aiming to give...

Wondering whether UP Fintech Holding offers genuine value at its current price, or if the recent excitement has already been priced in? This article breaks down what the numbers are saying about the stock. The share price sits at US$9.52 after a 7 day return of an 8.8% decline, a 30 day return of 3.0%, a year to date return of an 8.8% decline, a 1 year return of 54.5% and a 3 year return of 138.0%, while the 5 year return stands at a 36.2% decline. Recent coverage around UP Fintech Holding...

Constellation Brands (STZ) is back in focus after third quarter results topped expectations even as sales and profits softened, with management leaning on pricing, cost savings, dividends, and buybacks to steady the story. See our latest analysis for Constellation Brands. The latest results and capital return updates come after a mixed stretch for investors, with a 90 day share price return of 10.27% and an 8.49% year to date share price gain set against a 1 year total shareholder return of...

Why Waste Connections stock is drawing fresh attention Waste Connections (WCN) is back on investors’ radar after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months and year despite positive multi year performance. See our latest analysis for Waste Connections. The recent 6.5% 7 day share price decline and 6.4% year to date share price return have taken some momentum out of Waste Connections, even though the 5 year total shareholder...

Earlier this month, The Trade Desk announced that major publishers including AccuWeather, BuzzFeed, the Guardian, Hearst, Newsweek, People Inc., and Ziff Davis are backing its new OpenAds auction environment, which aims to give publishers and sellers a more direct, transparent way to run digital ad auctions. This broad publisher support highlights growing industry demand for higher-integrity programmatic auctions and positions OpenAds as a potential benchmark for transparency across the...

Procter & Gamble (PG) is back in focus after recent share moves, as investors weigh its consumer staples profile against mixed return figures over different time frames and a current share price of $144.24. See our latest analysis for Procter & Gamble. Recent trading has been steady rather than sharp, with a 7 day share price return of 3.1% on top of a year to date share price return of 1.7%. However, the 1 year total shareholder return of 7.3% and 5 year total shareholder return of 22.4%...

In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z). This setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a...

SS Innovations International recently issued preliminary, unaudited results indicating fourth-quarter 2025 revenue of about US$15.0 million and full-year 2025 revenue of about US$43.0 million, both sharply higher than 2024 levels and driven by increased SSi Mantra surgical robot sales and installations. Alongside this growth, the company expanded its leadership bench by appointing veteran executive Milan Rao as both Chief Financial Officer and Global Chief Operating Officer, underscoring its...

If you are wondering whether Teva Pharmaceutical Industries is still reasonably priced after its recent run, this article will walk through what the current share price might be implying about value. Teva's stock last closed at US$32.47, with returns of 1.1% over 7 days, 9.0% over 30 days, 4.9% year to date, 54.8% over 1 year and 194.6% over 3 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on Teva as investors...

Ultragenyx Pharmaceutical (RARE) is back in focus after reporting preliminary 2025 revenue guidance of US$672 million to US$674 million, which is above its prior range, alongside completing an FDA BLA submission for gene therapy candidate DTX401. See our latest analysis for Ultragenyx Pharmaceutical. The raised 2025 revenue guidance and DTX401 BLA completion come after a volatile period, with a 7 day share price return of 6.97% but a 30 day share price return of a 33.45% decline, and a 1 year...

Intel (INTC) is back in the spotlight after a cluster of analyst upgrades tied to surging AI server CPU demand, tighter 2026 capacity, progress on its 18A foundry ramp, and new Core Ultra Series 3 AI PC chips. See our latest analysis for Intel. Those AI driven headlines have played out in the share price too, with a 27.29% 90 day share price return, a 20.09% year to date share price return and a very large 1 year total shareholder return, suggesting momentum has been building as investors...

For investors considering whether Sarepta Therapeutics is a potential bargain or a value trap at its current share price, this article walks through what the numbers say about the stock. The share price recently closed at US$21.46, with returns of a 4.0% decline over 7 days, a 0.3% decline over 30 days, a 0.7% gain year to date, and declines of 81.9% over 1 year, 83.5% over 3 years, and 77.8% over 5 years. Recent coverage of Sarepta has focused on how the company fits into the high risk,...

Why Lennox International Is On Investors’ Radar Today Lennox International (LII) has caught attention after recent share performance, with the stock showing mixed returns across different periods and a last close of US$531 that some investors are reassessing. See our latest analysis for Lennox International. Recent price moves at Lennox International have been relatively steady, with a 4.99% 1 month share price return and a 6.43% year to date share price return. The 1 year total shareholder...

In recent weeks, Coinbase Global has outlined an ambitious push into tokenized equities, expanded institutional crypto services with Standard Chartered, and prepared a 31-product derivatives platform offering up to 10x leverage on major cryptocurrencies, while simultaneously clashing with U.S. lawmakers over potential limits on stablecoin rewards. This combination of innovation in tokenization and derivatives, deeper institutional integration, and regulatory tension around a key revenue...

If you are wondering whether Apple stock is still reasonably priced at its current level, this article will help you connect the share price to what the business may be worth using clear valuation checks. Apple shares last closed at US$261.05, with returns of a 0.5% decline over 7 days, a 6.2% decline over 30 days, a 3.7% decline year to date and 12.4% over 1 year, alongside very large 3 year and 5 year gains of 94.9% and 109.8%. These moves are happening as Apple continues to feature...

Ares Management (ARES) has drawn fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months, while longer term performance remains significantly higher. See our latest analysis for Ares Management. Against a longer backdrop of strong total shareholder return, including a 3 year total shareholder return of 136.01% and 5 year total shareholder return of 330.13%, the recent 1 day share price return of 2.91% decline and softer...

If you are wondering whether LendingClub's share price still lines up with its fundamentals, you are not alone. This article focuses squarely on what the current price might imply about value. With the stock at US$20.16 and returns of 0.9% over 7 days, 1.3% over 30 days, 5.4% year to date, 30.7% over 1 year and 99.6% over 3 years, many investors are asking how much of the story is already in the price. Recent attention on LendingClub has been shaped by ongoing discussion around its role in...

Merck stock reaction and recent return profile Merck (MRK) has drawn investor attention after a stretch of mixed short term performance, with a 0.9% decline over the past day, a 0.6% decline over the past week, and gains over the month and past 3 months. Against this backdrop, the stock’s 1 year total return of 12.7% and 5 year total return of 59.9% sit alongside a value score of 5. This combination prompts a closer look at how its current pricing lines up with its fundamentals. See our...